| Theme | Endocrine cell tumors of the colorectum: Difference in concept between WHO classification and Japanese classification | |
|---|---|---|
| Title | Systemic therapy for GEP neuroendocrine tumors | |
| Publish Date | 2019/02 | |
| Author | Masaru Fukahori | Multidisciplinary Cancer Treatment Center, Kurume University Hospital |
| Author | Keisuke Miwa | Multidisciplinary Cancer Treatment Center, Kurume University Hospital |
| Author | Sachiko Nagasu | Multidisciplinary Cancer Treatment Center, Kurume University Hospital |
| Author | Yasutaka Shimotsuura | Multidisciplinary Cancer Treatment Center, Kurume University Hospital |
| Author | Toshimitsu Tanaka | Multidisciplinary Cancer Treatment Center, Kurume University Hospital |
| Author | Tomoyuki Ushijima | Division of Gastroenterology, Department of Medicine, Kurume University |
| Author | Takahiko Sakaue | Division of Gastroenterology, Department of Medicine, Kurume University |
| Author | Yoshinobu Okabe | Division of Gastroenterology, Department of Medicine, Kurume University |
| Author | Osamu Tsuruta | Division of Gastroenterology, Department of Medicine, Kurume University |
| [ Summary ] | Gastroenteropancreatic neuroendocrine neoplasms (GEP-NENs) are a genetically diverse group of complex malignancies with varying biological and clinical courses. Established therapies include somatostatin analogues and systemic chemotherapy. The availability of novel agents and expression of targets, such as growth factor receptors, different types of somatostatin receptors, mammalian target of rapamycin (mTOR), multi-target TKI such as sunitinib and peptide receptor radionuclide therapy (PRRT) have led to the exploration of different classes of drug. This review provides an overview of novel drugs including a focus on the impact of recently approved drugs for NENs disease. | |